NCT05935748 2025-11-12Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)NiKang Therapeutics, Inc.Phase 2 Terminated18 enrolled
NCT05241340 2025-10-24RAD-VACCINEThe Methodist Hospital Research InstitutePhase 2 Active not recruiting33 enrolled